Company profile: C3J Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage bacteriophage therapeutics and a synthetic phage platform to engineer phages for multidrug-resistant infections, including AP-PA02 for Pseudomonas aeruginosa respiratory disease in cystic fibrosis and non-CF bronchiectasis, AP-PA03 for acute pneumonia (hospital-acquired and ventilator-associated), and AP-SA02 for Staphylococcus aureus bacteremia and potential prosthetic joint infections.
Products and services
- Synthetic Phage Platform: Uses synthetic biology to engineer phages with enhanced properties for treating multidrug-resistant bacterial infections, delivering custom-engineered phage assemblies for resistant bacterial targets
- AP-PA03: Phage cocktail developed for acute pneumonia caused by Pseudomonas aeruginosa, focusing on hospital-acquired and ventilator-associated pneumonia, as a hospital-grade product for pulmonary infection management
- AP-PA02: Phage cocktail targeting Pseudomonas aeruginosa for treating respiratory infections, particularly in cystic fibrosis and non-cystic fibrosis bronchiectasis patients, as a clinical-stage product for CF and NCFB respiratory disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to C3J Therapeutics
AutoGenomics
HQ: United States
Website
- Description: Provider of automated microarray-based multiplex molecular diagnostic platforms and genetic testing tools, including INFINITI System, INFINITI PLUS Analyzer, INFINITI High Throughput System, proprietary BioFilmChip microarrays, and assays such as AvertD for opioid use disorder risk and Factor II-V Leiden for thrombophilia, for disease signature assessment in women's health, cancer and personalized medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AutoGenomics company profile →
Epizyme
HQ: United States
Website
- Description: Provider of biopharmaceutical research and treatments focused on blood cancer and tumors. Based in Cambridge, MA and founded in 2007, the company translates epigenetic research into programs and offers Bylvay, a non-systemic ileal bile acid transport inhibitor for cholestatic pruritus in Alagille syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epizyme company profile →
Mammoth Biosciences
HQ: United States
Website
- Description: Provider of CRISPR-based diagnostics, therapeutics, and protein discovery solutions. The DETECTR Platform delivers instrument-free nucleic acid detection for disease; therapeutics offer precision genome editing using novel CRISPR-Cas enzymes; and a proprietary platform discovers new CRISPR systems and Cas proteins for applications in research, agriculture, and biodefense.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mammoth Biosciences company profile →
Verve Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage genetic medicines for cardiovascular disease, including gene editing therapies VERVE-101 targeting PCSK9 to lower LDL-C in heterozygous familial hypercholesterolemia and ASCVD, and VERVE-201 targeting ANGPTL3 for homozygous and refractory hypercholesterolemia, enabled by a proprietary GalNAc-LNP liver delivery system, with medicines evaluated in clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verve Therapeutics company profile →
Maze Therapeutics
HQ: United States
Website
- Description: Provider of precision medicines for renal, cardiovascular, and metabolic diseases, including MZE829, an oral candidate for APOL1 kidney disease that mimics protective genetic variants, and MZE001, an oral substrate reduction therapy for Pompe disease. Offers the Compass platform integrating variant functionalization into drug development and genetic medicine programs for chronic kidney and cardio-metabolic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Maze Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for C3J Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to C3J Therapeutics
2.2 - Growth funds investing in similar companies to C3J Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for C3J Therapeutics
4.2 - Public trading comparable groups for C3J Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →